Pettinati H M
Addiction Treatment Research Center, University of Pennsylvania, Philadelphia 19104-6178, USA.
Alcohol Clin Exp Res. 1996 Oct;20(7 Suppl):23A-29A. doi: 10.1111/j.1530-0277.1996.tb01186.x.
This study presents a review of existing human studies that examine the role of serotonin [5-hydroxytryptamine (5-HT)] selective agents in the treatment of alcohol dependence. Findings of abnormally low 5-HT levels in many alcohol-dependent patients led investigators to explore the use of 5-HT selective pharmacotherapy in the treatment of alcoholism. Several studies reported that the administration of 5-HT selective pharmacological agents to alcohol-dependent patients effectively reduced alcohol intake, although results have been relatively modest. The most recent study by Kranzler et al. (Am. J. Psychiatry 152:391-397, 1995) found no added benefit over cognitive-behavioral treatment. However, the original relationship between the presence of alcohol dependence and low 5-HT levels in the brains of patients with alcoholism was predicated on subtypes of alcohol dependence. Research has suggested that 5-HT plays an important role in some forms of alcoholism that may be genetically or developmentally mediated. Thus, additional studies are needed to determine if treatment with 5-HT selective agents is viable therapeutic option for alcoholism, specifically in types of alcohol-dependent patients who are most likely to benefit from treatment with 5-HT selective pharmacotherapy.
本研究对现有关于5-羟色胺[5-羟色胺(5-HT)]选择性药物在酒精依赖治疗中作用的人体研究进行了综述。许多酒精依赖患者5-HT水平异常低下的研究结果促使研究人员探索使用5-HT选择性药物疗法来治疗酒精中毒。多项研究报告称,对酒精依赖患者施用5-HT选择性药物可有效减少酒精摄入量,尽管效果相对有限。克兰兹勒等人(《美国精神病学杂志》152:391 - 397, 1995年)的最新研究发现,与认知行为疗法相比并无额外益处。然而,酒精依赖与酒精中毒患者大脑中5-HT水平低下之间的原始关系是基于酒精依赖的亚型。研究表明,5-HT在某些可能由遗传或发育介导的酒精中毒形式中发挥重要作用。因此,需要进一步研究以确定5-HT选择性药物治疗是否是酒精中毒的可行治疗选择,特别是对于最有可能从5-HT选择性药物疗法中受益的酒精依赖患者类型。